drugset / Trial / NCT06774859

Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Chinese Pediatric Participants 1 to <12 Years of Age With Influenza Symptoms

NCT06774859

Phase 3 Completed 100 enrolled Hoffmann-La Roche
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety of a single dose baloxavir marboxil compared with 5 days of oseltamivir administered twice a day (BID) in Chinese pediatric participants aged 1 to \< 12 years with influenza symptoms.

Timeline

Start
2024-10-27
Primary completion
2025-05-08
Completion
2025-05-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Baloxavir Marboxil Unknown 2 mg/kg Oral
Subject Baloxavir Marboxil Unknown 40 mg Oral
Subject Baloxavir Marboxil Unknown 80 mg Oral
Comparator Oseltamivir Small molecule 30 mg Oral
Comparator Oseltamivir Small molecule 45 mg Oral
Comparator Oseltamivir Small molecule 60 mg Oral
Comparator Oseltamivir Small molecule 75 mg Oral

Indications